About Raptor

Raptor is dedicated to speeding the delivery of new treatment options to patients by working to improve existing therapeutics through the application of highly specialized drug targeting platforms and formulation expertise. We focus on underserved patient populations where we can have the greatest potential impact.

  • Efficient: Raptor has built a robust and diversified product portfolio with great efficiency. In less than 4 years and $25 million, Raptor has built a NASDAQ-listed biopharmaceutical company with a product pipeline that may advance therapeutic options for 10 different indications and includes potential for both product launch and partnering revenue within the next 2 years.
  • Collaborative: Raptor has a track record of successful acquisitions and collaborations. We will continue to collaborate with academic and commercial partners in order to advance patient care. Since our inception in late 2005, Raptor has completed 9 product candidate and technology acquisitions.
  • Experienced: Our management team consists of repeat entrepreneurs with the experience to build a successful company. They have been involved in co-founding 5 companies including BioMarin Pharmaceutical, a fully integrated international biopharmaceutical company with a multi-billion dollar market capitalization.

Clinical development pipeline

We are developing DR Cysteamine for the potential treatment of:

Raptor has three clinical-stage product candidates for which we are seeking partners.

  • Convivia™ for the potential management of acetaldehyde toxicity due to ALDH2 Deficiency, an inherited metabolic disorder
  • Tezampanel and NGX426, non-opioids for the potential treatment of migraine and pain.

Preclinical program

In our preclinical program, Raptor is bioengineering novel drug candidates and drug-targeting platforms derived from the human receptor-associated protein (RAP) and related proteins to target cancer, neurodegenerative disorders and infectious diseases. Raptor's preclinical programs include HepTide™, WntTide™ and NeuroTrans™.

In June 2009, Raptor entered a collaboration and licensing agreement with Roche to evaluate therapeutic delivery of Roche's investigative molecules attached to Raptor’s proprietary NeuroTrans™ transporter platform.

Raptor is also examining its glutamate receptor antagonists, tezampanel and NGX426, for the prevention and treatment of thrombotic disorder. Research conducted at Johns Hopkins University (JHU) by Craig Morrell, D.V.M., Ph.D., and Charles Lowenstein, M.D. demonstrated the importance of glutamate release in promoting platelet activation and thrombosis. Research shows that AMPA/Kainate receptor antagonists including tezampanel (NGX424) retard thrombus development in vitro and in vivo.